MRUS - Merus N.V.
IEX Last Trade
42.37
-7.140 -16.852%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$49.51
-7.14
-14.42%
Fundamental analysis
26%
Profitability
25%
Dept financing
14%
Liquidity
50%
Performance
25%
Performance
5 Days
1.34%
1 Month
-6.57%
3 Months
-10.72%
6 Months
-25.31%
1 Year
56.67%
2 Year
189.09%
Key data
Stock price
$42.37
DAY RANGE
$42.79 - $49.51
52 WEEK RANGE
$28.24 - $61.46
52 WEEK CHANGE
$48.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Sven A. Lundberg
Region: US
Website: merus.nl
Employees: 37
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: merus.nl
Employees: 37
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Recent news